Thesis (M.S. in Operations Research)--Naval Postgraduate School, September 1990. / Thesis Advisor(s): McMasters, Alan W. ; Henderson, David R. "September 1990." Description based on title screen as viewed on December 21, 2009. DTIC Descriptor(s): Naval Procurement, Mathematical Models, Parameters, Navy, Theses, Costs, Precision, Procurement, Inventory, Value, Supplies, Naval Logistics, Models, Contracts, Decision Making. DTIC Identifier(s): Navy Inventory Control Points, Navy Procurement Contract Termination Model, Forecasts. Author(s) subject terms: Procurement, Contract, Termination. Includes bibliographical references (p. 57-58). Also available in print.

Thesis (M.S. in Management)--Naval Postgraduate School, December 2009. / Thesis Advisor: Gates, William R. Second Reader: Summers, Donald E. "December 2009." Description based on title screen as viewed on January 26, 2010. Author(s) subject terms: lease, purchase, Alternative-fuel Vehicle (AFV), incremental costs, salvage values, General Services Administration (GSA), United States Marine Corps (USMC), light-duty vehicle. Includes bibliographical references (p. 61-63). Also available in print.

Thesis--PlanB (M.S.)--University of Wisconsin--Stout, 2004. / Includes bibliographical references.

Thesis (M.B.A.)--Naval Postgraduate School, December 2003. / "MBA professional report"--Cover. Thesis advisor(s): David R. Henderson, Don E. Summers. Includes bibliographical references (p. 53-55). Also available online.

Thesis (M.Com.(Financial Management))--University of Pretoria, 2009. / Includes bibliographical references.

Thesis (MTech (Public Management))--Peninsula Technikon, 2002. / Word processed copy. Summary in English. Includes bibliographical references (leaves 110-113). Also available online.

In the current geopolitical environment, in which funding has dramatically diminished for many social service programs, policymakers and social workers have a significant challenge to advocate for social welfare policies, interventions, and treatments that are both cost effective and have the best outcomes. In order to advocate effectively, it is crucial to understand the components that contribute to the cost of mental illness. Information regarding these costs, although they greatly affect policies and public mental health, are not readily represented in the social sciences. The objective of this dissertation is to describe methodological approaches, identify concepts within mental health economics, and address constructs in an attempt to introduce them to the social work field. This dissertation sought to explore and contribute new information to the literature on the direct and indirect economic cost of mental illness and the implications for the field of social work. It will consist of three publishable quality articles that examine issues associated with the economic cost of mental illness. A conceptual paper examining various elements that contextualize the range of economic costs is first utilized. It identifies, defines, and describes the economic cost of mental illness, discusses the history and factors that influence this cost, examine the current state of research including theories and methodological approaches and limitations. Next, an analysis on the range of information technology surrounding mental health and related economic cost is presented. This dissertation article will identify, describe and analyze database sets utilized in economic evaluation. There are four database sets that are the focus of this article. This article will compare, contrast, and critique the datasets on their various components; applicability; and reliability in terms of the usage for economic valuation for planning and evaluation within social work research. Finally, a quantitative study is undertaken that examines how the economy can influence how patients with mental episodes are handled. This study aimed to examine the relationship between State Mental Health Agency expenditures and revenues and its impact on three types of psychiatric admissions: Voluntarily Admitted, Involuntarily Civilly Committed, and Involuntarily Criminally Committed. / text

Introduction: Current treatment recommendations for advanced SCCHN include the use of combined modality therapy (e.g., radiation plus chemotherapy/biologic therapy). The new biologic agent, cetuximab, is considered a primary cost driver for SCCHN management. Cetuximab’s impact, however, has not been factored into SCCHN cost estimates; furthermore, costs have not been delineated for diagnostic, treatment, and end-of-life segments of advanced SCCHN management. We aim to characterize SCCHN segmented and overall costs, before and after cetuximab’s approval. Methods: This was a retrospective analysis of the PharMetrics Choice database. Patients >20 years of age with ICD-9-CM codes suggestive of advanced SCCHN diagnosed between 3/1/2003 and 3/1/2008 were included. Patients were divided into cohorts by diagnosis date: “pre-biologic” and “post-biologic.” Descriptive statistics were used to summarize patient characteristics, monthly and total medical costs, and cost drivers. The Mann-Whitney U test was used to compare costs between segments and cohorts; whereas, least squares regression was used to ascertain the impact of covariates. Results: A total of 365 patients met study criteria. Patients were predominately male (78%), with a median age of 57 years. Median monthly costs were: diagnosis ($2,199), treatment ($4,161), end-of-life ($6,614), and total ($4,167). Total direct medical costs were primarily driven by outpatient costs (23%). Patient age and length of follow-up had a significant impact on total costs, with older age associated with lower costs. When treatment segment was isolated, median monthly costs were lower in the “pre-biologic” as compared to the “post-biologic” era ($3,301 vs. $4,381, p=0.0024); biologic therapy accounted for 4.2% of total cost in the study period. In those patients experiencing all segments of care (“benchmark group”), median monthly costs were: diagnosis ($1,733), treatment ($8,265), end-of-life ($6,614), and total ($7,817). There were no significant differences in monthly medical costs between cohorts for the benchmark group. Conclusions: Median total cost exceeded $4,000/month for SCCHN patients; treatment and end-of-life segments incurred higher costs. Outpatient costs were the biggest cost-driver. Median monthly cost for the treatment segment increased by approximately $1,000 following cetuximab’s approval; however, this difference dissipated when the analysis was limited to those patients who experienced all segments of care. / text

Not available / text

This item was digitized as part of the Million Books Project led by Carnegie Mellon University and supported by grants from the National Science Foundation (NSF). Cornell University coordinated the participation of land-grant and agricultural libraries in providing historical agricultural information for the digitization project; the University of Arizona Libraries, the College of Agriculture and Life Sciences, and the Office of Arid Lands Studies collaborated in the selection and provision of material for the digitization project.